Embla Medical – Presentation of Q3 2025 Interim Report

You can already now sign up for the event and send in your questions. You don’t have to participate live to submit questions for the event.

Embla Medical will release its Q3 2025 interim report on October 21, 2025. On the same day at 10:30 CEST, the company’s management will present the results and answer questions during a live online event.

Embla Medical’s Q2 2025 results showed an increase in organic growth to 5%, up from 4% in the first quarter. Growth, as in Q1, was driven by the Prosthetics & Neuro Orthotics business segment and, regionally, by the APAC and EMEA markets. The Patient Care segment and the US market continued to lag, although there was a slight improvement compared to Q1 2025. EBITDA margins for the first half of the year improved by 1 percentage point compared to the same period last year, reaching 20%.

Based on the first half-year results, the company narrowed its 2025 outlook for organic growth to 5–6% (previously 5–8%) but reaffirmed its expectation of an EBITDA margin of 20–21%.

With guidance indicating a pickup in the second half of the year, the focus around the Q3 results will be whether the results confirm these expectations for a stronger H2 2025. In addition to the financial results, investor attention may also focus on the momentum in the newly launched Navii and Icon bionic knees, and the fact that a main competitor has announced its intention to IPO in the latter part of 2025.

Embla Medical is a leading global provider of innovative mobility solutions in the medical technology space. The company enhances people’s mobility through the development and delivery of Prosthetics & Neuro Orthotics, Bracing & Supports, and Patient Care.

Dislcaimer: HC Andersen Capital receives payment from Embla Medical for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis, 16.32, 24-09-2025.